On November 29th, 2022, the second-to-last trading day of the month on the NASDAQ, RLX (stock code: RLX) opened with a significant 11% increase, reaching $2.27 per share. At the close of trading that day, the stock had risen by 7%, closing at $2.20 per share.
RLX Technology's (RLX) stock performance on the US market was reported by Yahoo Finance yesterday.
As of yesterday's closing, Yueke's November cumulative increase in the US stock market was 76%, rising from $1.25 at the close of October 31 to $2.20 at yesterday's close.
The stock performance of Fog Core Technology (RLX) on the US stock market this month, according to Yahoo Finance.
The first domestic clinical study on electronic cigarettes has been published in the medical SCI journal "Nicotine and Tobacco Research". The study confirms that the pharmacokinetic characteristics of nicotine in electronic cigarettes are similar to those in traditional cigarettes and may be used to alleviate withdrawal symptoms. The study was initiated and funded by Wuxi-based Fogcore Technology and was registered in China's Clinical Trial Registration Center (ChiCTR) and the World Health Organization International Clinical Trial Registration Platform (WHO ICTRP) as the first domestic clinical research project on electronic cigarettes.
Research Summary from chictr
Wuxin Technologies co-founder and CEO Wang Ying stated in the financial report:
In the third quarter of 2022, we remain committed to preparing for a smooth transition to the new national standards, which will come into full effect on October 1, 2022. Specifically, we have reduced the shipment of old products and gradually transitioned towards a region-based trading platform that follows the new standards. We have achieved nationwide coverage through this platform.
According to a report from Reuters on October 29th, a recent assessment conducted by Standard & Poor's Global Corporate Sustainability Assessment (CSA) has revealed that Huixing Technology is the top-performing electronic cigarette company in the world in terms of environmental, social, and governance (ESG) criteria. This news may have positively impacted the recent rise in stock prices for Juul Labs, which occurred earlier this month.
Today (November 30th) is the last trading day of the month and 2FIRSTS will continue to monitor the stock performance of Yueke in the United States. Please stay tuned for updates.
Author/Zhu Hongxu
References:
Standard & Poor's has released RLX's ESG score report, which shows that the company has been ranked ahead of its global peers.
The Chinese Clinical Trial Registry has conducted a study on the nicotine metabolism kinetics of traditional cigarettes and electronic cigarettes among healthy subjects in China. The study also investigates the effects of completely or partially replacing cigarettes with e-cigarettes on human biomarkers and measures the tolerability and satisfaction of e-cigarettes.
Further reading:
Yueke's third-quarter financial report shows a year-on-year decrease of 600 million yuan in net income.
Yueke, a company, states that there is a great deal of uncertainty in their future operations.
2FIRSTS will continue to report on this issue, with updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
